Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Macular DegenerationWet Macular DegenerationRetinal DegenerationRetinal DiseasesEye Diseases
Interventions
DRUG

Aflibercept

Intravitreal Injection

Trial Locations (9)

21033

Hôpital général de Dijon, Dijon

33000

Hôpital Pellegrin, Bordeaux

38330

Cabinet Alpes Rétine, Montbonnot-Saint-Martin

44093

CHR Hôtel Dieu, Nantes

69003

Centre d'Ophtalmologie Rabelais, Lyon

75006

Centre d'explorations ophtalmologiques de l'odéon, Paris

75012

Hôpital des Quinze-Vingts, Paris

76100

Clinique Mathilde, Rouen

94010

Centre Hospitalier Intercommunal de Créteil, Créteil

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Centre Hospitalier Intercommunal Creteil

OTHER

NCT02157077 - Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter